Welcome to Avior!

We are an R&D-stage pharmaceutical company that owns a powerful, patent-pending delivery technology called Speedit™ – based our ability to create drug nanoparticles in a cost-effective way called compositional quenching.  Such nanoparticles can be used as an injectable dosage form or incorporated in tablets and films to provide high bioavailability of lipophilic drugs.

To complete our proof-of-concept, we are developing prototypes with a candidate drug molecule – AV-104 – for testing in preclinical animal studies for early market entry in 2021 for the treatment of chronic kidney disease (CKD) associated pruritus seeking FDA approval in 4Q2020 through a 505b2 regulatory roadmap. Currently, there are no drugs approved for this indication.

We are happy to speak with you to unlock the potential of our powerful technology platform for your needs.

Please join us on this voyage!


We make stability, drug nanoparticles using a concept called Compositional Quenching. Such particles range from nanometer to micrometer sizes and can be easily incorporated in tablets, films, suspensions to the targeted dosage form.

Product in Development

AV-104 will be the first once-daily sublingual tablet for the treatment of Prurigo Nodularis and Chronic Kidney Disease (CKD) – associated Pruritus.  AV-104 is a mixed biased GPCR agonist-antagonist, thus reducing the manifestation of  Prurigo Nodularis.


For more information, please contact:

Niraj Vasisht, PhD
President and CEO
Avior Inc.

230 Shillings Chase Drive
Cary, NC 27518